We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Mnx5.5
Minoxidil (oral & topical) Research
Mostly mechanism / observationalLimited safety
8 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Minoxidil (oral & topical) studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality meta-analyses and randomised trials published 2002–2025 with a typical study size of 352 participants.
Based on 8 studies · 1 meta-analysis · 4 RCTs · 3,004 total participants
Confidence
Moderate
By outcome
Hair regrowth
Mostly mechanism / observational8 studies
Safety & tolerability
Mostly mechanism / observational3 studies
Cardiovascular effects
Too few graded studies2 studies
Active research area
5 studies in the last 5 years · Latest meta-analysis: 2025
200220132025
1RCTn=393 · medium study2002
After 48 weeks, 5% topical minoxidil was superior to 2% minoxidil and placebo for hair regrowth in men with androgenetic alopecia.
Olsen, Dunlap, Funicella, Koperski, Swinehart, Tschen · Journal of the American Academy of Dermatology (2002)
48-week double-blind, placebo-controlled, multicenter RCT in 393 men with androgenetic alopecia
Compared 5% solution, 2% solution, and placebo applied twice daily
5% outperformed 2% and placebo on target-area hair counts and patient/investigator assessments
Once-daily 5% minoxidil foam and twice-daily 2% minoxidil solution both induced hair regrowth in female pattern hair loss, but prespecified noninferiority criteria were not met.
Blume-Peytavi, Shapiro, Messenger, Hordinsky, Zhang, Quiza · Journal of drugs in dermatology : JDD (2016)
Phase III randomized, investigator-blinded trial in 322 women with female pattern hair loss
Once-daily 5% foam vs twice-daily 2% solution; primary endpoint at 24 weeks
Both arms increased target-area hair count and were numerically comparable, but the prespecified noninferiority goal was NOT met (difference -0.3 hairs/cm2, 95% CI -6.0 to 5.4, crossing the -5.0 margin)
4RCT2024
Daily oral minoxidil 5 mg was comparable to twice-daily topical minoxidil 5% over 24 weeks in male androgenetic alopecia.
In 1404 patients, hypertrichosis was the most common adverse effect of low-dose oral minoxidil; systemic effects were infrequent and rarely caused withdrawal.
Vañó-Galván, Pirmez, Hermosa-Gelbard, Moreno-Arrones, Saceda-Corralo, Rodrigues-Barata · Journal of the American Academy of Dermatology (2021)
Retrospective multicenter cohort of 1404 patients on low-dose oral minoxidil for alopecia
Hypertrichosis (15.1%) was the most frequent adverse effect; only 0.5% withdrew for it
In patients with hypertension or arrhythmia, low-dose oral minoxidil caused systemic adverse effects in 6.8% of cases, mostly lightheadedness and fluid retention.